Search

Your search keyword '"Pao, William"' showing total 505 results
Start Over Author "Pao, William" Publication Type Academic Journals
505 results on '"Pao, William"'

8. Investigation of the liquid carryovers in the branching T-junction, based on historical data.

Author

Ejaz, Faheem, Pao, William, Ali, Hafiz Muhammad, and Saieed, Ahmed

Subjects
*OFFSHORE oil & gas industry, *DIGITIZATION, *PHASE separation, *LIQUIDS, *RESEARCH personnel, *DESIGN software
Abstract

High liquid content is obtained in the T-junction side arm, which affects the operational performance of downstream equipment installed in offshore petroleum industries. Diameter ratio, velocity ratio, and side arm angle of T-junction play dynamic role to control phase redistribution. The effect of these parameters on liquid take-offs is unclear from literature, without any agreement among researchers. Literature only provides empirical correlations valid for one specific application for which the correlations were developed. There is a dire need of correlations with high accuracies to conclude the effect of a certain variable on liquid carryovers based on available data. Objectives of this study are to collect data from multiple research publications, develop easy to use correlations, and to study parameters response surfaces. Plot digitization and Design Expert software are utilized for data collection and statistical analysis, respectively. Results depicted that phase separation improves by reducing diameter ratio to 0.33 and upward inclined side arm. Furthermore, liquid carryovers escalate by increasing velocity ratio and decrease at higher velocity ratios. This research study is first attempt in last few decades which is based on collection of data from different experimentation facilities and eliminating confusions among researchers about effect of parameters on phase separation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Facilitating a culture of responsible and effective sharing of cancer genome data

Author

Siu, Lillian L, Lawler, Mark, Haussler, David, Knoppers, Bartha Maria, Lewin, Jeremy, Vis, Daniel J, Liao, Rachel G, Andre, Fabrice, Banks, Ian, Barrett, J Carl, Caldas, Carlos, Camargo, Anamaria Aranha, Fitzgerald, Rebecca C, Mao, Mao, Mattison, John E, Pao, William, Sellers, William R, Sullivan, Patrick, Teh, Bin Tean, Ward, Robyn L, ZenKlusen, Jean Claude, Sawyers, Charles L, and Voest, Emile E

Subjects
Health Services and Systems, Health Sciences, Health Services, Human Genome, Cancer, Clinical Research, Genetics, Biotechnology, Good Health and Well Being, Computational Biology, Culture, Databases, Genetic, Genome, Humans, Information Dissemination, Neoplasms, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Rapid and affordable tumor molecular profiling has led to an explosion of clinical and genomic data poised to enhance the diagnosis, prognostication and treatment of cancer. A critical point has now been reached at which the analysis and storage of annotated clinical and genomic information in unconnected silos will stall the advancement of precision cancer care. Information systems must be harmonized to overcome the multiple technical and logistical barriers to data sharing. Against this backdrop, the Global Alliance for Genomic Health (GA4GH) was established in 2013 to create a common framework that enables responsible, voluntary and secure sharing of clinical and genomic data. This Perspective from the GA4GH Clinical Working Group Cancer Task Team highlights the data-aggregation challenges faced by the field, suggests potential collaborative solutions and describes how GA4GH can catalyze a harmonized data-sharing culture.

Published
2016

18. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning

Author

Hosgood, H Dean, Pao, William, Rothman, Nathaniel, Hu, Wei, Pan, Yumei Helen, Kuchinsky, Kyle, Jones, Kirk D, Xu, Jun, Vermeulen, Roel, Simko, Jeff, and Lan, Qing

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Tobacco, Clinical Research, Lung, Health Effects of Indoor Air Pollution, Cancer, Genetics, Tobacco Smoke and Health, Lung Cancer, Prevention, 2.2 Factors relating to the physical environment, Aetiology, Respiratory, Good Health and Well Being, Adenocarcinoma, Adult, Air Pollution, Indoor, Carcinoma, Squamous Cell, Cell Differentiation, Coal, ErbB Receptors, Female, Gene-Environment Interaction, Genetic Predisposition to Disease, Humans, Lung Neoplasms, Middle Aged, Mutation, Neoplasm Proteins, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Smoke, Smoking, Young Adult, ras Proteins, EGFR, KRAS, Lung cancer, Never smoking, China, Driver mutations, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Respiratory System, Cardiovascular medicine and haematology
Abstract

Lung cancer in never smokers, which has been partially attributed to household solid fuel use (i.e., coal), is etiologically and clinically different from lung cancer attributed to tobacco smoking. To explore the spectrum of driver mutations among lung cancer tissues from never smokers, specifically in a population where high lung cancer rates have been attributed to indoor air pollution from domestic coal use, multiplexed assays were used to detect >40 point mutations, insertions, and deletions (EGFR, KRAS, BRAF, HER2, NRAS, PIK3CA, MEK1, AKT1, and PTEN) among the lung tumors of confirmed never smoking females from Xuanwei, China [32 adenocarcinomas (ADCs), 7 squamous cell carcinomas (SCCs), 1 adenosquamous carcinoma (ADSC)]. EGFR mutations were detected in 35% of tumors. 46% of these involved EGFR exon 18 G719X, while 14% were exon 21 L858R mutations. KRAS mutations, all of which were G12C_34G>T, were observed in 15% of tumors. EGFR and KRAS mutations were mutually exclusive, and no mutations were observed in the other tested genes. Most point mutations were transversions and were also found in tumors from patients who used coal in their homes. Our high mutation frequencies in EGFR exon 18 and KRAS and low mutation frequency in EGFR exon 21 are strikingly divergent from those in other smoking and never smoking populations from Asia. Given that our subjects live in a region where coal is typically burned indoors, our findings provide new insights into the pathogenesis of lung cancer among never smoking females exposed to indoor air pollution from coal.

Published
2013

20. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Author

Azzoli, Christopher G, Temin, Sarah, Aliff, Timothy, Baker, Sherman, Brahmer, Julie, Johnson, David H, Laskin, Janessa L, Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pao, William, Pfister, David G, Piantadosi, Steven, Schiller, Joan H, Smith, Reily, Smith, Thomas J, Strawn, John R, Trent, David, and Giaccone, Giuseppe

Subjects
Clinical Trials and Supportive Activities, Cancer, Lung Cancer, Lung, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Carcinoma, Non-Small-Cell Lung, Clinical Trials, Phase III as Topic, Humans, Lung Neoplasms, Neoplasm Staging, Randomized Controlled Trials as Topic, American Society of Clinical Oncology, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeAn American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy.Clinical contextRecent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable.Recent dataSeven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-line therapy.RecommendationIn patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

Published
2011

21. Inhibition of Drug-Resistant Mutants of ABL, KIT, and EGF Receptor Kinases

Author

Carter, Todd A., Wodicka, Lisa M., Shah, Neil P., Velasco, Anne Marie, Fabian, Miles A., Treiber, Daniel K., Milanov, Zdravko V., Atteridge, Corey E., Biggs,, William H., Edeen, Philip T., Floyd, Mark, Ford, Julia M., Grotzfeld, Robert M., Herrgard, Sanna, Insko, Darren E., Mehta, Shamal A., Patel, Hitesh K., Pao, William, Sawyers, Charles L., Varmus, Harold, Zarrinkar, Patrick P., and Lockhart, David J.

Published
2005

22. [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

Author

Azzoli, Christopher G, Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H, Laskin, Janessa L, Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G, Piantadosi, Steven, Schiller, Joan H, Smith, Reily, Smith, Thomas J, Strawn, John R, Trent, David, and Giaccone, Giuseppe

Subjects
Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Neoplasm Staging, Antineoplastic Protocols, Societies, Medical, United States, Guidelines as Topic, Oncology & Carcinogenesis
Published
2010

24. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Author

Azzoli, Christopher G, Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H, Laskin, Janessa L, Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G, Piantadosi, Steven, Schiller, Joan H, Smith, Reily, Smith, Thomas J, Strawn, John R, Trent, David, and Giaccone, Giuseppe

Subjects
Lung, Clinical Trials and Supportive Activities, Cancer, Rare Diseases, Clinical Research, Orphan Drug, Lung Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging, American Society of Clinical Oncology, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

Published
2009

26. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

Author

Gao, Sizhi Paul, Mark, Kevin G, Leslie, Kenneth, Pao, William, Motoi, Noriko, Gerald, William L, Travis, William D, Bornmann, William, Veach, Darren, Clarkson, Bayard, and Bromberg, Jacqueline F

Subjects
Cell Line, Tumor, Animals, Humans, Mice, Mice, Nude, Adenocarcinoma, Lung Neoplasms, RNA, Small Interfering, Interleukin-6, Enzyme Inhibitors, Neoplasm Transplantation, Signal Transduction, Transcription, Genetic, Gene Expression Regulation, Neoplastic, Phosphorylation, Mutation, Female, STAT3 Transcription Factor, Cytokine Receptor gp130, Janus Kinases, ErbB Receptors, Lung, Cancer, Lung Cancer, Medical and Health Sciences, Immunology
Abstract

Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.

Published
2007

37. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types

Author

Sampson, Joshua N., Wheeler, William A., Yeager, Meredith, Panagiotou, Orestis, Wang, Zhaoming, Berndt, Sonja I., Lan, Qing, Abnet, Christian C., Amundadottir, Laufey T., Figueroa, Jonine D., Landi, Maria Teresa, Mirabello, Lisa, Savage, Sharon A., Taylor, Philip R., Vivo, Immaculata De, McGlynn, Katherine A., Purdue, Mark P., Rajaraman, Preetha, Adami, Hans-Olov, Ahlbom, Anders, Albanes, Demetrius, Amary, Maria Fernanda, An, She-Juan, Andersson, Ulrika, Andriole, Gerald, Jr., Andrulis, Irene L., Angelucci, Emanuele, Ansell, Stephen M., Arici, Cecilia, Armstrong, Bruce K., Arslan, Alan A., Austin, Melissa A., Baris, Dalsu, Barkauskas, Donald A., Bassig, Bryan A., Becker, Nikolaus, Benavente, Yolanda, Benhamou, Simone, Berg, Christine, Van Den Berg, David, Bernstein, Leslie, Bertrand, Kimberly A., Birmann, Brenda M., Black, Amanda, Boeing, Heiner, Boffetta, Paolo, Boutron-Ruault, Marie-Christine, Bracci, Paige M., Brinton, Louise, Brooks-Wilson, Angela R., Bueno-de-Mesquita, H. Bas, Burdett, Laurie, Buring, Julie, Butler, Mary Ann, Cai, Qiuyin, Cancel-Tassin, Geraldine, Canzian, Federico, Carrato, Alfredo, Carreon, Tania, Carta, Angela, Chan, John K. C., Chang, Ellen T., Chang, Gee-Chen, Chang, I-Shou, Chang, Jiang, Chang-Claude, Jenny, Chen, Chien-Jen, Chen, Chih-Yi, Chen, Chu, Chen, Chung-Hsing, Chen, Constance, Chen, Hongyan, Chen, Kexin, Chen, Kuan-Yu, Chen, Kun-Chieh, Chen, Ying, Chen, Ying-Hsiang, Chen, Yi-Song, Chen, Yuh-Min, Chien, Li-Hsin, Chirlaque, María-Dolores, Choi, Jin Eun, Choi, Yi Young, Chow, Wong-Ho, Chung, Charles C., Clavel, Jacqueline, Clavel-Chapelon, Françoise, Cocco, Pierluigi, Colt, Joanne S., Comperat, Eva, Conde, Lucia, Connors, Joseph M., Conti, David, Cortessis, Victoria K., Cotterchio, Michelle, Cozen, Wendy, Crouch, Simon, Crous-Bou, Marta, Cussenot, Olivier, Davis, Faith G., Ding, Ti, Diver, W. Ryan, Dorronsoro, Miren, Dossus, Laure, Duell, Eric J., Ennas, Maria Grazia, Erickson, Ralph L., Feychting, Maria, Flanagan, Adrienne M., Foretova, Lenka, Fraumeni, Joseph F., Jr, Freedman, Neal D., Beane Freeman, Laura E., Fuchs, Charles, Gago-Dominguez, Manuela, Gallinger, Steven, Gao, Yu-Tang, Gapstur, Susan M., Garcia-Closas, Montserrat, García-Closas, Reina, Gascoyne, Randy D., Gastier-Foster, Julie, Gaudet, Mia M., Gaziano, J. Michael, Giffen, Carol, Giles, Graham G., Giovannucci, Edward, Glimelius, Bengt, Goggins, Michael, Gokgoz, Nalan, Goldstein, Alisa M., Gorlick, Richard, Gross, Myron, Grubb, Robert, III, Gu, Jian, Guan, Peng, Gunter, Marc, Guo, Huan, Habermann, Thomas M., Haiman, Christopher A., Halai, Dina, Hallmans, Goran, Hassan, Manal, Hattinger, Claudia, He, Qincheng, He, Xingzhou, Helzlsouer, Kathy, Henderson, Brian, Henriksson, Roger, Hjalgrim, Henrik, Hoffman-Bolton, Judith, Hohensee, Chancellor, Holford, Theodore R., Holly, Elizabeth A., Hong, Yun-Chul, Hoover, Robert N., Horn-Ross, Pamela L., Hosain, G. M. Monawar, Hosgood, H. Dean, III, Hsiao, Chin-Fu, Hu, Nan, Hu, Wei, Hu, Zhibin, Huang, Ming-Shyan, Huerta, Jose-Maria, Hung, Jen-Yu, Hutchinson, Amy, Inskip, Peter D., Jackson, Rebecca D., Jacobs, Eric J., Jenab, Mazda, Jeon, Hyo-Sung, Ji, Bu-Tian, Jin, Guangfu, Jin, Li, Johansen, Christoffer, Johnson, Alison, Jung, Yoo Jin, Kaaks, Rudolph, Kamineni, Aruna, Kane, Eleanor, Kang, Chang Hyun, Karagas, Margaret R., Kelly, Rachel S., Khaw, Kay-Tee, Kim, Christopher, Kim, Hee Nam, Kim, Jin Hee, Kim, Jun Suk, Kim, Yeul Hong, Kim, Young Tae, Kim, Young-Chul, Kitahara, Cari M., Klein, Alison P., Klein, Robert J., Kogevinas, Manolis, Kohno, Takashi, Kolonel, Laurence N., Kooperberg, Charles, Kricker, Anne, Krogh, Vittorio, Kunitoh, Hideo, Kurtz, Robert C., Kweon, Sun-Seog, LaCroix, Andrea, Lawrence, Charles, Lecanda, Fernando, Lee, Victor Ho Fun, Li, Donghui, Li, Haixin, Li, Jihua, Li, Yao-Jen, Li, Yuqing, Liao, Linda M., Liebow, Mark, Lightfoot, Tracy, Lim, Wei-Yen, Lin, Chien-Chung, Lin, Dongxin, Lindstrom, Sara, Linet, Martha S., Link, Brian K., Liu, Chenwei, Liu, Jianjun, Liu, Li, Ljungberg, Börje, Lloreta, Josep, Lollo, Simonetta Di, Lu, Daru, Lund, Eiluv, Malats, Nuria, Mannisto, Satu, Marchand, Loic Le, Marina, Neyssa, Masala, Giovanna, Mastrangelo, Giuseppe, Matsuo, Keitaro, Maynadie, Marc, McKay, James, McKean-Cowdin, Roberta, Melbye, Mads, Melin, Beatrice S., Michaud, Dominique S., Mitsudomi, Tetsuya, Monnereau, Alain, Montalvan, Rebecca, Moore, Lee E., Mortensen, Lotte Maxild, Nieters, Alexandra, North, Kari E., Novak, Anne J., Oberg, Ann L., Offit, Kenneth, Oh, In-Jae, Olson, Sara H., Palli, Domenico, Pao, William, Park, In Kyu, Park, Jae Yong, Park, Kyong Hwa, Patiño-Garcia, Ana, Pavanello, Sofia, Peeters, Petra H. M., Perng, Reury-Perng, Peters, Ulrike, Petersen, Gloria M., Picci, Piero, Pike, Malcolm C., Porru, Stefano, Prescott, Jennifer, Prokunina-Olsson, Ludmila, Qian, Biyun, Qiao, You-Lin, Rais, Marco, Riboli, Elio, Riby, Jacques, Risch, Harvey A., Rizzato, Cosmeri, Rodabough, Rebecca, Roman, Eve, Roupret, Morgan, Ruder, Avima M., Sanjose, Silvia de, Scelo, Ghislaine, Schned, Alan, Schumacher, Fredrick, Schwartz, Kendra, Schwenn, Molly, Scotlandi, Katia, Seow, Adeline, Serra, Consol, Serra, Massimo, Sesso, Howard D., Setiawan, Veronica Wendy, Severi, Gianluca, Severson, Richard K., Shanafelt, Tait D., Shen, Hongbing, Shen, Wei, Shin, Min-Ho, Shiraishi, Kouya, Shu, Xiao-Ou, Siddiq, Afshan, Sierrasesúmaga, Luis, Sihoe, Alan Dart Loon, Skibola, Christine F., Smith, Alex, Smith, Martyn T., Southey, Melissa C., Spinelli, John J., Staines, Anthony, Stampfer, Meir, Stern, Marianna C., Stevens, Victoria L., Stolzenberg-Solomon, Rachael S., Su, Jian, Su, Wu-Chou, Sund, Malin, Sung, Jae Sook, Sung, Sook Whan, Tan, Wen, Tang, Wei, Tardón, Adonina, Thomas, David, Thompson, Carrie A., Tinker, Lesley F., Tirabosco, Roberto, Tjønneland, Anne, Travis, Ruth C., Trichopoulos, Dimitrios, Tsai, Fang-Yu, Tsai, Ying-Huang, Tucker, Margaret, Turner, Jenny, Vajdic, Claire M., Vermeulen, Roel C. H., Villano, Danylo J., Vineis, Paolo, Virtamo, Jarmo, Visvanathan, Kala, Wactawski-Wende, Jean, Wang, Chaoyu, Wang, Chih-Liang, Wang, Jiu-Cun, Wang, Junwen, Wei, Fusheng, Weiderpass, Elisabete, Weiner, George J., Weinstein, Stephanie, Wentzensen, Nicolas, White, Emily, Witzig, Thomas E., Wolpin, Brian M., Wong, Maria Pik, Wu, Chen, Wu, Guoping, Wu, Junjie, Wu, Tangchun, Wu, Wei, Wu, Xifeng, Wu, Yi-Long, Wunder, Jay S., Xiang, Yong-Bing, Xu, Jun, Xu, Ping, Yang, Pan-Chyr, Yang, Tsung-Ying, Ye, Yuanqing, Yin, Zhihua, Yokota, Jun, Yoon, Ho-Il, Yu, Chong-Jen, Yu, Herbert, Yu, Kai, Yuan, Jian-Min, Zelenetz, Andrew, Zeleniuch-Jacquotte, Anne, Zhang, Xu-Chao, Zhang, Yawei, Zhao, Xueying, Zhao, Zhenhong, Zheng, Hong, Zheng, Tongzhang, Zheng, Wei, Zhou, Baosen, Zhu, Meng, Zucca, Mariagrazia, Boca, Simina M., Cerhan, James R., Ferri, Giovanni M., Hartge, Patricia, Hsiung, Chao Agnes, Magnani, Corrado, Miligi, Lucia, Morton, Lindsay M., Smedby, Karin E., Teras, Lauren R., Vijai, Joseph, Wang, Sophia S., Brennan, Paul, Caporaso, Neil E., Hunter, David J., Kraft, Peter, Rothman, Nathaniel, Silverman, Debra T., Slager, Susan L., Chanock, Stephen J., and Chatterjee, Nilanjan

Published
2015
Full Text
View/download PDF

38. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Author

Ohashi, Kadoaki, Sequist, Lecia V., Arcila, Maria E., Moran, Teresa, Chmielecki, Juliann, Lin, Ya-Lun, Pan, Yumei, Wang, Lu, de Stanchina, Elisa, Shien, Kazuhiko, Aoe, Keisuke, Toyooka, Shinichi, Kiura, Katsuyuki, Fernandez-Cuesta, Lynnette, Fidias, Panos, Yang, James Chih-Hsin, Miller, Vincent A., Riely, Gregory J., Kris, Mark G., Engelman, Jeffrey A., Vnencak-Jones, Cindy L., Dias-Santagata, Dora, Ladanyi, Marc, and Pao, William

Published
2012

39. Anchored multiplex PCR for targeted next-generation sequencing

Author

Zheng, Zongli, Liebers, Matthew, Zhelyazkova, Boryana, Cao, Yi, Panditi, Divya, Lynch, Kerry D., Chen, Juxiang, Robinson, Hayley E., Shim, Hyo Sup, Chmielecki, Juliann, Pao, William, Engelman, Jeffrey A., Iafrate, A. John, and Le, Long Phi

Subjects
Nucleotide sequencing -- Methods -- Research, DNA sequencing -- Methods -- Research, Polymerase chain reaction -- Usage -- Research, Biological sciences, Health
Abstract

We describe a rapid target enrichment method for next-generation sequencing, termed anchored multiplex PCR (AMP), that is compatible with low nucleic acid input from formalin-fixed paraffin-embedded (FFPE) specimens. AMP is effective in detecting gene rearrangements (without prior knowledge of the fusion partners), single nucleotide variants, insertions, deletions and copy number changes. Validation of a gene rearrangement panel using 319 FFPE samples showed 100% sensitivity (95% confidence limit: 96.5-100%) and 100% specificity (95% confidence limit: 99.3-100%) compared with reference assays. On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma. AMP is a scalable and efficient next-generation sequencing target enrichment method for research and clinical applications., Next-generation sequencing has been instrumental in the advancement of genomic research and clinical molecular diagnostics in recent years. Although the cataloguing of complete genomes and their variation is an important [...]

Published
2014
Full Text
View/download PDF

41. Identifying Genotype-Dependent Efficacy of Single and Combined PI3K- and MAPK-Pathway Inhibition in Cancer

Author

Sos, Martin L., Fischer, Stefanie, Ullrich, Roland, Peifer, Martin, Heuckmann, Johannes M., Koker, Mirjam, Heynck, Stefanie, Stückrath, Isabel, Weiss, Jonathan, Fischer, Florian, Michel, Kathrin, Goel, Aviva, Regales, Lucia, Politi, Katerina A., Perera, Samanthi, Getlik, Matthäus, Heukamp, Lukas C., Ansén, Sascha, Zander, Thomas, Beroukhim, Rameen, Kashkar, Hamid, Shokat, Kevan M., Sellers, William R., Rauh, Daniel, Orr, Christine, Hoeflich, Klaus P., Friedman, Lori, Wong, Kwok-Kin, Pao, William, and Thomas, Roman K.

Published
2009
Full Text
View/download PDF

42. The Tyrosine Phosphatase PTPRD Is a Tumor Suppressor That Is Frequently Inactivated and Mutated in Glioblastoma and Other Human Cancers

Author

Veeriah, Selvaraju, Brennan, Cameron, Meng, Shasha, Singh, Bhuvanesh, Fagin, James A., Solit, David B., Paty, Philip B., Rohle, Dan, Vivanco, Igor, Chmielecki, Juliann, Pao, William, Ladanyi, Marc, Gerald, William L., Liau, Linda, Cloughesy, Timothy C., Mischel, Paul S., Sander, Chris, Taylor, Barry, Schultz, Nikolaus, Major, John, Heguy, Adriana, Fang, Fang, Mellinghoff, Ingo K., Chan, Timothy A., and Vogelstein, Bert

Published
2009
Full Text
View/download PDF

43. Preliminary Results of Numerical Simulation of Slug Flow in a Regular T-Junction

Author

Tran Minh, Memon Zeeshan, Pao William, and Hashim Fakhruldin M

Subjects
Engineering (General). Civil engineering (General), TA1-2040
Abstract

Excessive liquid carryover in T-junction due to splitting nature of two-phase flow causes serious issues in piping system. A three-dimensional numerical model is employed to investigate two-phase flow split behavior of slug flow in a circular-section regular T-junction with 0.0752 m diameter. The Volume of Fraction method combined with k-ε turbulence model and initial sinusoidal perturbation in ANSYS FLUENT is adopted to characterize the effect of slug flow behavior on the phase separation efficiency. The preliminary result reveals that the simulation work can study slug flow split in great detail and the slug characteristic plays an important role in understanding split behavior.

Published
2018
Full Text
View/download PDF

47. MET Amplification Occurs with or without T790M Mutations in EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib

Author

Bean, James, Brennan, Cameron, Shih, Jin-Yuan, Riely, Gregory, Viale, Agnes, Wang, Lu, Chitale, Dhananjay, Motoi, Noriko, Szoke, Janos, Broderick, Stephen, Balak, Marissa, Chang, Wen-Cheng, Yu, Chong-Jen, Gazdar, Adi, Pass, Harvey, Rusch, Valerie, Gerald, William, Huang, Shiu-Feng, Yang, Pan-Chyr, Miller, Vincent, Ladanyi, Marc, Yang, Chih-Hsin, and Pao, William

Published
2007
Full Text
View/download PDF

49. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women

Author

Wang, Zhaoming, Seow, Wei Jie, Shiraishi, Kouya, Hsiung, Chao A., Matsuo, Keitaro, Liu, Jie, Chen, Kexin, Yamji, Taiki, Yang, Yang, Chang, I-Shou, Wu, Chen, Hong, Yun-Chul, Burdett, Laurie, Wyatt, Kathleen, Chung, Charles C., Li, Shengchao A., Yeager, Meredith, Hutchinson, Amy, Hu, Wei, Caporaso, Neil, Landi, Maria T., Chatterjee, Nilanjan, Song, Minsun, Fraumeni, Joseph F., Jr, Kohno, Takashi, Yokota, Jun, Kunitoh, Hideo, Ashikawa, Kyota, Momozawa, Yukihide, Daigo, Yataro, Mitsudomi, Tetsuya, Yatabe, Yasushi, Hida, Toyoaki, Hu, Zhibin, Dai, Juncheng, Ma, Hongxia, Jin, Guangfu, Song, Bao, Wang, Zhehai, Cheng, Sensen, Yin, Zhihua, Li, Xuelian, Ren, Yangwu, Guan, Peng, Chang, Jiang, Tan, Wen, Chen, Chien-Jen, Chang, Gee-Chen, Tsai, Ying-Huang, Su, Wu-Chou, Chen, Kuan-Yu, Huang, Ming-Shyan, Chen, Yuh-Min, Zheng, Hong, Li, Haixin, Cui, Ping, Guo, Huan, Xu, Ping, Liu, Li, Iwasaki, Motoki, Shimazu, Taichi, Tsugane, Shoichiro, Zhu, Junjie, Jiang, Gening, Fei, Ke, Park, Jae Yong, Kim, Yeul Hong, Sung, Jae Sook, Park, Kyong Hwa, Kim, Young Tae, Jung, Yoo Jin, Kang, Chang Hyun, Park, In Kyu, Kim, Hee Nam, Jeon, Hyo-Sung, Choi, Jin Eun, Choi, Yi Young, Kim, Jin Hee, Oh, In-Jae, Kim, Young-Chul, Sung, Sook Whan, Kim, Jun Suk, Yoon, Ho-Il, Kweon, Sun-Seog, Shin, Min-Ho, Seow, Adeline, Chen, Ying, Lim, Wei-Yen, Liu, Jianjun, Wong, Maria Pik, Lee, Victor Ho Fun, Bassig, Bryan A., Tucker, Margaret, Berndt, Sonja I., Chow, Wong-Ho, Ji, Bu-Tian, Wang, Junwen, Xu, Jun, Sihoe, Alan Dart Loon, Ho, James C.M., Chan, John K.C., Wang, Jiu-Cun, Lu, Daru, Zhao, Xueying, Zhao, Zhenhong, Wu, Junjie, Chen, Hongyan, Jin, Li, Wei, Fusheng, Wu, Guoping, An, She-Juan, Zhang, Xu-Chao, Su, Jian, Wu, Yi-Long, Gao, Yu-Tang, Xiang, Yong-Bing, He, Xingzhou, Li, Jihua, Zheng, Wei, Shu, Xiao-Ou, Cai, Qiuyin, Klein, Robert, Pao, William, Lawrence, Charles, Hosgood, H. Dean, III, Hsiao, Chin-Fu, Chien, Li-Hsin, Chen, Ying-Hsiang, Chen, Chung-Hsing, Wang, Wen-Chang, Chen, Chih-Yi, Wang, Chih-Liang, Yu, Chong-Jen, Chen, Hui-Ling, Su, Yu-Chun, Tsai, Fang-Yu, Chen, Yi-Song, Li, Yao-Jen, Yang, Tsung-Ying, Lin, Chien-Chung, Yang, Pan-Chyr, Wu, Tangchun, Lin, Dongxin, Zhou, Baosen, Yu, Jinming, Shen, Hongbing, Kubo, Michiaki, Chanock, Stephen J., Rothman, Nathaniel, and Lan, Qing

Published
2016
Full Text
View/download PDF

50. The NIH-led research response to COVID-19.

Author

Collins, Francis, Adam, Stacey, Colvis, Christine, Desrosiers, Elizabeth, Draghia-Akli, Ruxandra, Fauci, Anthony, Freire, Maria, Gibbons, Gary, Hall, Matthew, Hughes, Eric, Jansen, Kathrin, Kurilla, Michael, Lane, H. Clifford, Lowy, Douglas, Marks, Peter, Menetski, Joseph, Pao, William, Pérez-Stable, Eliseo, Purcell, Lisa, and Read, Sarah

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results